ArticleWorld journal of gastrointestinal surgery2025
Clinical efficacy of neoadjuvant chemotherapy combined with radical gastrectomy in elderly patients with advanced gastric cancer.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemotherapy combined with radical gastrectomy is a safe and effective treatment for elderly patients with advanced gastric cancer. Despite the increased risk of pulmonary complications, such as pleural effusion and pulmonary infection, postoperative recovery time and survival outcomes are similar to younger patients.
aimTo investigate the safety and efficacy of neoadjuvant chemotherapy combined with radical gastrectomy in elderly patients with advanced gastric cancer by comparing treatment-related complications, surgical outcomes, and long-term survival between elderly patients (≥ 65 years) and younger patients (< 65 years).
methodsThe clinical data of 148 patients with advanced gastric cancer in elderly patients who received neoadjuvant chemotherapy in our hospital from January 2015 to October 2023 were retrospectively analyzed, and these patients were divided into young and middle-aged groups (111 patients) and elderly groups (37 patients), and their clinicopathology and prognosis were compared.
resultsNeoadjuvant chemotherapy induced anemia (
conclusionNeoadjuvant chemotherapy combined with radical gastrectomy is safe and effective in elderly patients with advanced gastric cancer, but there are more pulmonary complications (specifically pleural effusion and pulmonary infection) during the perioperative period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.